Bergenfelz Caroline, Leandersson Karin
Department of Translational Medicine, Division of Experimental Infection Medicine, Lund University, Malmö, Sweden.
Department of Translational Medicine, Cancer Immunology, Lund University, Skåne University Hospital, Malmö, Sweden.
Front Oncol. 2020 Feb 7;10:109. doi: 10.3389/fonc.2020.00109. eCollection 2020.
Myeloid-derived suppressor cells (MDSCs) are cells of myeloid lineage with a potent immunosuppressive capacity. They are present in cancer patients as well as in patients with severe inflammatory conditions and infections. MDSCs exist as two main subtypes, the granulocytic (G-MDSCs) and the monocytic (Mo-MDSCs) type, as defined by their surface phenotype and functions. While the functions of MDSCs have been investigated in depth, the origin of human MDSCs is less characterized and even controversial. In this review, we recapitulate theories on how MDSCs are generated in mice, and whether this knowledge is translatable into human MDSC biology, as well as on problems of defining MDSCs by their immature cell surface phenotype in relation to the plasticity of myeloid cells. Finally, the challenge of pharmacological targeting of MDSCs in the future is envisioned.
髓系来源的抑制性细胞(MDSCs)是具有强大免疫抑制能力的髓系细胞。它们存在于癌症患者以及患有严重炎症和感染的患者体内。根据其表面表型和功能,MDSCs主要分为两种亚型,即粒细胞型(G-MDSCs)和单核细胞型(Mo-MDSCs)。虽然对MDSCs的功能进行了深入研究,但人类MDSCs的起源却鲜为人知,甚至存在争议。在这篇综述中,我们总结了关于MDSCs在小鼠体内如何产生的理论,以及这些知识是否可转化为人类MDSC生物学,同时也总结了根据其未成熟细胞表面表型定义MDSCs与髓系细胞可塑性相关的问题。最后,展望了未来对MDSCs进行药物靶向治疗的挑战。